JPMorgan Chase & Co. Reduces Stake in Sionna Therapeutics, Inc.

JPMorgan Chase & Co. has filed an amendment to its Schedule 13G, disclosing a reduction in its stake in Sionna Therapeutics, Inc. The filing indicates that JPMorgan Chase & Co. now holds 1,980,626 shares, representing a 4.4% ownership in the company. This marks a significant decrease of 5,616,709 shares, or 73.93%, from its previous holdings. The shares are held through JPMorgan Chase Bank, National Association, and J.P. Morgan Investment Management Inc. The filing also certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing the control of the issuer.